Yaohua Zhang
Adjunct Assistant Professor
Boston University School of Public Health

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Zhang Y, Chu C, Beckman RA, Gao L, Laird G, Yi B. A confirmatory basket design considering non-inferiority and superiority testing. J Biopharm Stat. 2024 Mar; 34(2):205-221. PMID: 36988397; DOI: 10.1080/10543406.2023.2192781;
  2. Fajac I, Daines C, Durieu I, Goralski JL, Heijerman H, Knoop C, Majoor C, Bruinsma BG, Moskowitz S, Prieto-Centurion V, Van Brunt K, Zhang Y, Quittner A. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2023 Jan; 22(1):119-123. PMID: 36114142; DOI: 10.1016/j.jcf.2022.08.018;
  3. Viswanathan L, Bachman E, Tian S, Ahluwalia N, Zhang Y, Bernstein HS, Panorchan P. Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet. 2022 Nov; 47(6):817-825. PMID: 36036885; PMCID: PMC9633523; DOI: 10.1007/s13318-022-00791-8;
  4. Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 Aug 26; 385(9):815-825. PMID: 34437784; PMCID: PMC8982185; DOI: 10.1056/NEJMoa2100665;
  5. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 Nov 23; 394(10212):1940-1948. PMID: 31679946; PMCID: PMC7571408; DOI: 10.1016/S0140-6736(19)32597-8;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 5 publications over 4 distinct years, with a maximum of 2 publications in 2022


2017 University of Connecticut: Doctoral Dissertation Fellowship
2017 Quality and Productivity Research Conference: Travel Award
2015 Quality and Productivity Research Conference: Travel Award
2015 From Industrial Statistics to Data Science Conference: Travel Award
Contact for Mentoring:

801 Massachusetts Ave
Boston MA 02118
Google Map

Zhang's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department